Intellia Therapeutics Receives Orphan Drug Designation for NTLA-2002 in the EU

1 Mins read

Intellia Therapeutics, a leading biotechnology company, has recently been granted orphan drug designation by the European Commission for their investigational therapy, NTLA-2002. This therapy shows promise in the treatment of hereditary angioedema (HAE), a condition characterized by potentially life-threatening swelling attacks.

Positive Impact on Stock

Following this significant development, Intellia Therapeutics experienced a surge in their shares, with a 10% increase, reaching $26.10. This comes as a relief to the company, as their stock had hit a low point of $22.67 earlier this week, resulting in a 51% overall decrease in the past year.

Promising Research on NTLA-2002

NTLA-2002 is an innovative in vivo CRISPR-based therapy specially designed to prevent swelling attacks in individuals with HAE. This therapy has shown potential in combating this condition and offering hope to patients.

Orphan Drug Designation Process

In receiving orphan drug designation from the European Union, Intellia Therapeutics has successfully met the rigorous criteria set by the European Medicines Agency Committee for Orphan Medicinal Products. This designation is reserved for therapies intended to treat, prevent, or diagnose life-threatening or chronically debilitating diseases that affect a limited number of people in the EU population (not exceeding five in 10,000 individuals).

Recognition and Future Potential

Intellia Therapeutics’ NTLA-2002 has not only been granted orphan drug designation by the European Commission but has also received this prestigious recognition from the U.S. Food and Drug Administration. With five special regulatory designations already obtained for NTLA-2002, there is growing confidence in the therapeutic potential of this innovative solution.

Related posts

Alaska Air Group Inc. to Acquire Hawaiian Airlines

1 Mins read
Alaska Air Group Inc. has recently announced its plan to acquire Hawaiian Airlines in a deal worth approximately $1.9 billion. The transaction…

The State of the U.S. Labor Market

2 Mins read
This week, all eyes will be on the U.S. labor market as the Federal Reserve’s December meeting approaches. The release of November…

Ceres Power Holdings Faces Revenue Setback

1 Mins read
Ceres Power Holdings, a leading fuel-cell technology company, experienced a sharp decline in its shares on Friday. The company announced that its…

Leave a Reply

Your email address will not be published. Required fields are marked *